Skip to Main Content

An advocacy group has asked the National Institutes of Health to investigate whether several patents held by Aegerion Pharmaceuticals failed to disclose federal funding for grants that were used to develop a pricey cholesterol treatment.

In its request, the advocacy group cited a federal database showing six patents were awarded to the University of Pennsylvania, where an academic researcher used NIH grants to develop a drug called Juxtapid, which was later licensed to Aegerion Pharmaceuticals. The school has received more than $68 million in grants for research led by Dr. Daniel Rader, who chairs the genetics department at the Perelman School of Medicine, and at least $293,000 pertained to his work on Juxtapid, according to Knowledge Ecology International, the advocacy group.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!